Capecitabine News and Research

RSS

AI reveals effective combination therapy for advanced rectal cancer

Artificial intelligence developed by researchers at UCL has revealed a promising combination of cancer treatments that could help patients with locally advanced rectal cancer live longer.

27 Jul 2026

Immunotherapy plus chemotherapy improves outcomes in stage III dMMR colon cancer

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

25 Mar 2026

Combination therapy shows promise for leptomeningeal metastasis in breast cancer

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

18 Mar 2026

KFF Health News' 'What the Health?': RFK Jr. upends vaccine policy, after promising he wouldn’t

After explicitly promising senators during his confirmation hearing that he would not interfere in scientific policy over which Americans should receive which vaccines, Health and Human Services Secretary Robert F. Kennedy Jr. this week fired every member of the Advisory Committee on Immunization Practices, the group of experts who help the Centers for Disease Control and Prevention make those evidence-based judgments.

12 Jun 2025

Two patients faced chemo. The one who survived demanded a test to see if it was safe.

JoEllen Zembruski-Ruple, while in the care of New York City's renowned Memorial Sloan Kettering Cancer Center, swallowed the first three chemotherapy pills to treat her squamous cell carcinoma on Jan. 29, her family members said. They didn't realize the drug could kill her.

4 Jun 2025

Exercise after chemo key for colon cancer survival, study finds

Post-chemotherapy exercise significantly boosts disease-free survival in colon cancer patients, underscoring the importance of structured physical activity.

3 Jun 2025

New ASTRO guideline offers radiation therapy recommendations for anal cancer

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat adult patients with primary squamous cell carcinoma (SCC) of the anal canal and anal margin.

27 Feb 2025

FarrSight-Twin technology transforms cancer treatment research

Researchers have shown that they can accurately re-create clinical trials of new treatments using 'digital twins' of real cancer patients.

24 Oct 2024

HER2-postive breast cancer drugs show promise for bile duct cancer treatment

Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

23 Oct 2024

Long radiotherapy course shows better organ preservation in rectal cancer

The COVID-19 pandemic has enabled researchers to show that a long course of radiotherapy given before surgery may be a better treatment for avoiding surgery, preserving the rectum and anus, and preventing regrowth of the primary tumor than a short course of radiotherapy for patients with rectal cancer – a type of bowel cancer.

11 Sep 2024

Overdosing on chemo: A common gene test could save hundreds of lives each year

One January morning in 2021, Carol Rosen took a standard treatment for metastatic breast cancer. Three gruesome weeks later, she died in excruciating pain from the very drug meant to prolong her life.

26 Mar 2024

New drug combo fights breast cancer with brain metastases

A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast cancer, compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

6 Dec 2023

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomized clinical trial in China.

8 Nov 2023

Trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer

The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also be used as monotherapy for the treatment of adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy at this disease stage or developed disease recurrence early after adjuvant chemotherapy.

31 Oct 2023

New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

23 Aug 2023

Clinical trial tests effectiveness of chemotherapy after surgery for pancreatic neuroendocrine tumors

A new clinical trial is testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.

19 May 2023

T-DXd shows high efficacy in HER2-positive breast cancer patients previously treated with T-DM1

Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

7 Dec 2022

Study estimates the cost-effectiveness of therapeutic alternatives

Giving standard chemotherapy drugs in a specific sequence for some types of metastatic breast cancer can help reduce overall costs and improve the value of care while preserving quality of life, according to a study led by UNC Lineberger Comprehensive Cancer Center and UNC Gillings School of Global Public Health researchers.

14 Sep 2022

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health's Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone.

6 Jun 2022

Scientists identify a new method to treat triple-negative breast cancer

A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR's Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less aggressive ('epithelial') to being more aggressive ('mesenchymal'), and vice versa.

7 Oct 2021